Document:

<PAGE>

                                                                EXHIBIT 10.13(c)

                   TOLL MANUFACTURING AND PACKAGING AGREEMENT

      This Toll Manufacturing and Packaging Agreement (this "Agreement") is made
as of this 31st day of October, 2000, by and between Cephalon, Inc., 145
Brandywine Parkway, West Chester, PA 19380-4245 ("CEPHALON") and Abbott
Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064-6029 ABBOTT
("ABBOTT").

      WHEREAS, CEPHALON holds certain rights to manufacture, market and sell in
the United States the pharmaceutical product, which is marketed and sold as
Gabitril(R);

      WHEREAS, CEPHALON wishes to engage ABBOTT to formulate and package
Gabitril tablets in dosage form for subsequent commercial sale by CEPHALON in
the United States and for certain clinical and other purposes; and

      WHEREAS, ABBOTT has suitable facilities and equipment and sufficient
qualified personnel to formulate and package commercial quantities of Gabitril
in dosage form, and is willing to provide such services on the terms and
conditions set forth below.

      NOW, THEREFORE, the parties hereto, intending to be legally bound, agree
as follows:

I. DEFINITIONS

      As used in this Agreement:

      1.1   "Active Drug Substance" means the compound N-(4, 4-di
            (3-methyl-2-thienyl) but-3-en-1-yl) nipecotic acid, which is more
            commonly known as tiagabine having those specifications as set forth
            on Schedule A hereto.

      1.2   "Adverse Experience" or "AE" shall mean any unfavorable and
            unintended change in the structure, function, or chemistry of the
            body temporally associated with any use of a Product or of a
            derivative thereof, whether or not the adverse experience is
            considered to be related to the use of the Product, including but
            not limited to any of the following: an unexpected side effect,
            injury, toxicity or sensitivity reaction, which may include an
            experience of unexpected incidence and severity; an adverse
            experience occurring in the course of the use of a drug product in
            professional practice; an adverse experience occurring in clinical
            studies; an adverse experience occurring from drug overdose, whether
            accidental or intentional; an adverse experience occurring from drug
            abuse; an adverse experience occurring from drug withdrawal; and any
            significant failure of expected pharmacological action.

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

      1.3   "Affiliate" means any corporation or other business entity which,
            directly or indirectly, is controlled by, controls, or is under
            common control with CEPHALON or ABBOTT. For this purpose, "control"
            shall be deemed to mean ownership of fifty percent (50%) or more of
            the stock or other equity of such entity.

      1.4   "Commodities" means the raw materials necessary to package the
            Product as set forth in Schedule A hereto.

      1.5   "Components" means the raw material necessary to formulate the
            Product as set forth in Schedule A hereto.

      1.6   "Confidential Information" means all information, data, know-how and
            all other business, technical and financial data disclosed hereunder
            by one party or any of its Affiliates to the other party or any of
            its Affiliates, except any portion thereof which:

            (a)   at the time of disclosure, is public knowledge;

            (b)   after disclosure, becomes public knowledge by publication or
                  otherwise, except by breach of this Agreement by the
                  recipient;

            (c)   the recipient can demonstrate by its written records was in
                  the recipient's possession at the time of such disclosure, and
                  which was not acquired, directly or indirectly, from the
                  disclosing party;

            (d)   is lawfully disclosed to the recipient on a non-confidential
                  basis by a third party who is not obligated to the disclosing
                  party or any other third party to retain such Confidential
                  Information in confidence;

            (e)   results from research and development by the recipient
                  independent of such disclosure as shown by competent evidence;
                  or

            (f)   is required to be disclosed by legal process; provided, in
                  each case the party so disclosing information timely informs
                  the other party and uses its reasonable efforts to limit the
                  disclosure and maintain confidentiality to the extent possible
                  and, if possible, permits the other party to attempt by
                  appropriate legal means to limit such disclosure.

            Written Confidential Information shall be identified by the
            disclosing party as being confidential by stamping the cover pages
            of such information "Confidential." Confidential Information
            disclosed orally, visually and/or in another tangible form shall be
            identified by the disclosing party to the receiving

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

            party as confidential at the time of such disclosure and confirmed
            to the receiving party within thirty (30) days after such disclosure
            in a writing marked "Confidential."

       1.7  "Net Sales" means the gross invoice price of Product actually billed
            in the Territory by CEPHALON, a CEPHALON Affiliate or a CEPHALON
            sublicensee to independent third party customers less: (i) any
            direct or indirect credits and allowances or adjustments granted to
            customers including, without limitation, credits and allowances on
            account of price adjustments or on account of rejection or return of
            Product previously sold; (ii) any trade and cash discounts, rebates
            and distributor fees; (iii) any sales, excise, turnover or similar
            taxes and any duties and other governmental charges imposed upon the
            production, importation, use or sale of the Product; and (iv)
            applicable transportation, insurance and handling charges.

      1.8   "Product" means Gabitril in final packaged dosage forms meeting the
            Product specifications set forth in Schedule A hereto.

      1.9   "Quality Manual" means the form of quality assurance/quality control
            agreement to be entered into by CEPHALON and ABBOTT as set forth in
            Schedule B

      110.  "Territory" means the United States of America, including Puerto
            Rico and the territories and possessions of the United States of
            America.

      1.11  "Trademark" or "Trademarks" shall mean Gabitril(R), as well as any
            other trademark owned or used by CEPHALON in connection with the
            Product, including, but not limited to, those trademarks listed on
            Schedule A hereto.

II. APPOINTMENT AND TERM

      2.1   Appointment. CEPHALON hereby appoints ABBOTT, and ABBOTT hereby
            accepts appointment, as a toll manufacturer to formulate and package
            the Product.

      2.2   Manufacturing and Packaging Services. During the term of this
            Agreement, ABBOTT shall formulate Product, and prepare the Product
            for CEPHALON commercial sale to customers and for clinical and other
            purposes. In addition, ABBOTT shall label and package Product in
            accordance with those specifications and instructions set forth in
            Schedule A hereto, or otherwise as may be provided by CEPHALON and
            reasonably agreed to by ABBOTT in writing. CEPHALON will supply
            approved artwork for labels, package inserts and packaging. The
            content of the labels, package inserts and packaging shall be the
            sole and exclusive responsibility of CEPHALON. Notwithstanding the
            above, until ABBOTT's existing stock of Product is depleted, but for
            no longer than One Hundred Eighty (180) days from the effective date
            of this Agreement, Abbott shall

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

            continue to use the existing labeling for the Product which has
            ABBOTT's name and logo on Product for sale and ABBOTT's and
            CEPHALON's name and logo on Product for samples. As soon as
            practical after the depletion of such existing Product, Abbott shall
            label and package the Product as described above.

      2.3   Cooperation. CEPHALON and ABBOTT will cooperate with each other as
            may be necessary and customary in consideration of industry
            practice, and will disclose all material information necessary to
            enable each other to perform under this Agreement in a timely
            fashion.

      2.4   Specific Duties. In addition to its general obligations relating to
            formulating and packaging, ABBOTT shall perform the following
            services at ABBOTT's cost, except where indicated:

            (i)   placing orders for, acquiring and storing all Active Drug
                  Substance, Commodities and Components;

            (ii)  quality control and testing of all Active Drug Substance,
                  Commodities and Components, in process materials, bulk tablets
                  and finished dosage Product, in order to monitor compliance
                  with all applicable standards and specifications required by
                  this Agreement, including any Schedules hereto;

            (iii) conducting stability testing of Product in accordance with the
                  procedures set forth in the Quality Manual;

            (iv)  summarizing implemented changes and supplying latest versions
                  of approved critical documentation, and providing other
                  information necessary for CEPHALON to prepare, submit, obtain
                  and maintain all regulatory filings relating to the
                  manufacture of the Product under the terms of this Agreement;
                  and

            (v)   performing such other services as agreed upon in writing by
                  the parties.

      2.5   Term. Unless terminated in accordance with the provisions of Article
            XXIII, this Agreement will become effective and remain in effect for
            a period of five (5) years from the Effective Date as defined in
            that certain Gabitril Product Agreement (the "Gabitril Agreement")
            by and between ABBOTT and CEPHALON dated as of October 31, 2000 (the
            "Initial Term"), and, unless either party gives written notice of
            non-renewal at least one hundred eighty (180) days prior to the end
            of the Initial Term (or any renewal term), this Agreement shall be
            renewed for consecutive terms of two years.

III. PRODUCT QUANTITY, QUALITY AND MANUFACTURING PROCESSES

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

      3.1   Quantity. Subject to the terms and conditions of this Agreement,
            ABBOTT will manufacture, package and supply to CEPHALON quantities
            of Product ordered by CEPHALON or an Affiliate thereof for
            subsequent sale by CEPHALON or an Affiliate or sublicensee thereof
            or for certain clinical or other purposes in the Territory. ABBOTT
            agrees to reserve capacity for the quantities of Product as defined
            in Schedule C. ABBOTT shall have no obligation to supply quantities
            in excess of those set forth in Schedule C, but shall use its
            commercially reasonable efforts to accommodate CEPHALON demand for
            excess quantities. ABBOTT agrees to supply CEPHALON with samples of
            Product in the amounts set forth in Schedule C.

      3.2   Quality. All Product manufactured and packaged by ABBOTT for
            CEPHALON under this Agreement will meet the Product, Component and
            Commodities specifications set forth in Schedule A hereto (the
            "Specifications"), as well as the quality assurance standards
            established in the Quality Manual. Such Specifications, as well as
            the terms and conditions of the Quality Manual , are subject to
            modification from time to time by mutual written agreement of the
            parties. Prior to implementation of any Specification changes, the
            Parties agree to negotiate in good faith in an attempt to reach
            agreement on (a) the new price for any Product manufactured
            hereunder by ABBOTT which embodies such changes, based solely on the
            effect of such changes on ABBOTT's manufacturing costs for the
            Product and (b) any other amendments to this Agreement which may be
            necessitated by such changes (i.e., an adjustment to the lead time
            for purchase orders). CEPHALON agrees to reimburse ABBOTT for the
            reasonable, documented expenses incurred by ABBOTT as a result of
            such changes, including, but not limited to, reimbursing ABBOTT for
            its validation and development costs, capital expenditure costs and
            costs for any packaging components or other materials and in-process
            materials rendered unusable as a result of such changes. If during
            the term of this Agreement CEPHALON amends or is required by law to
            amend the Specifications so as to render Active Drug Substance,
            Commodities and/or Components or in-process materials for the
            Product obsolete, CEPHALON shall purchase from ABBOTT, [**], that
            amount of inventory of Active Drug Substance, Commodities and/or
            Components, in-process materials and/or Product, as the case may be,
            so rendered obsolete.

      3.3   Manufacturing Processes. ABBOTT has furnished to CEPHALON a copy of
            its production procedures and in the Quality Manual the parties will
            agree upon the equipment to be used to produce the Product. Costs
            incurred by ABBOTT as a result of any such changes or modifications
            requested by the FDA or by CEPHALON and relating solely to the
            production of the Product will be borne by CEPHALON; costs for other
            changes affecting ABBOTT's cGMP compliance or affecting other
            products generally will be borne by ABBOTT.

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

      3.4   Documentation. ABBOTT shall provide CEPHALON with initial methods
            and specifications for manufacturing and packaging the Product as
            set forth in the attached Schedule A. ABBOTT shall also promptly
            provide CEPHALON with all available safety data and information
            concerning the Product, process and related materials, including
            without limitation all MSDS's.

      3.5   Communication. ABBOTT and CEPHALON will respond to requests for
            support, information and approvals within [**] days. If a complete
            response is not possible within such [**] period, the party owing
            the response shall communicate within such [**] period the reason
            for the delay and when the response will be available.

      3.6   Quality Manual. Within sixty (60) days after the date of this
            Agreement, representatives of the parties' Quality Assurance
            departments shall meet to develop, agree and approve a Quality
            Manual outlining responsibilities and key contacts for quality and
            compliance related issues. ABBOTT will provide CEPHALON with certain
            production and control information for review prior to release as
            specified in the Quality Manual. The Quality Manual will also
            address, without limitation, annual product reviews, returned goods,
            regulatory audits, compliance with FDA current Good Manufacturing
            Practices, and such other quality related concerns deemed
            appropriate. The final agreed Quality Manual will use the form
            attached to this Agreement as Schedule B as a template and will be
            attached to and deemed a part of this Agreement when completed.

IV. CONFIDENTIAL INFORMATION

      4.1   The parties acknowledge that they have provided Confidential
            Information to each other in connection with the formulation and
            packaging of the Product, and further acknowledge that all such
            Confidential Information (as well as any additional Confidential
            Information provided by one party to the other hereunder) shall be
            subject to the provisions of this Article V. Any and all
            information, knowledge, technology, and trade secrets relating to
            the Product and provided by CEPHALON shall be deemed Confidential
            Information.

      4.2   ABBOTT will disclose to CEPHALON all Confidential Information
            concerning the Product developed by or for ABBOTT during the term of
            this Agreement, promptly as it is developed.

      4.3   During the term of this Agreement and for [**] thereafter, all
            Confidential Information disclosed or confirmed in writing and
            designated as confidential by the disclosing party, shall be held in
            confidence by the receiving party, shall not be used by the
            receiving party for any purpose except as provided hereunder and
            shall not be disclosed to third parties except for disclosure to its
            Affiliates or

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

            governmental authorities, or except as otherwise necessary to carry
            out the receiving party's obligations under this Agreement. If a
            receiving party finds it necessary to disclose such Confidential
            Information to a third party, the receiving party will not do so
            without first obtaining the written consent of the disclosing party
            (which shall not be unreasonably withheld) and entering into an
            agreement with the third party which binds the third party to the
            same obligations of restricted use and disclosure as are undertaken
            by the parties in this Agreement.

      4.4   Neither party shall distribute any Confidential Information of the
            other except to its employees or agents who have a need to know in
            connection with the performance of their duties in satisfying the
            obligations of such party hereunder. Any employee or agent who
            receives Confidential Information shall be advised as to the
            confidential nature thereof and the prohibitions contained herein.
            All copies of any portions of any Confidential Information
            distributed as provided in this section will be identified as
            confidential. Upon termination of this Agreement, and upon the
            request of the disclosing party, the receiving party shall return or
            destroy all such Confidential Information and any copies thereof in
            its possession, except that each party may retain one copy of
            Confidential Information solely for archival purposes.

      4.5   Termination of this Agreement shall not operate to extinguish either
            party's obligation to treat Confidential Information as provided
            herein, and the same shall continue in effect in accordance with
            this Article for [**] from the termination or expiration of this
            Agreement with respect to such Confidential Information.

      4.6   Nothing contained herein shall be deemed to grant either party,
            either expressed or implied, a license or other right or interest in
            the Confidential Information of the other or in any patent,
            trademark or other similar property of the other, except as
            expressly provided hereunder.

      4.7   Neither party shall use the name of the other, nor disclose the
            existence of this Agreement for any purpose, without the prior
            written consent of the other, which shall not be unreasonably
            withheld or delayed.

V. ACTIVE AND COMPONENT SUPPLY

      5.1   Active Drug Substance, Commodities and Components. ABBOTT will
            obtain at its expense Active Drug Substance, Commodities and
            Components which meets the specifications established in Schedule A.
            ABBOTT assumes full responsibility and liability for the storage and
            handling of all Active Drug Substance, Commodities and Components.

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

      5.2   Commodities. ABBOTT will label and package the Product in accordance
            with instructions and specifications provided by CEPHALON. ABBOTT
            will submit to CEPHALON for CEPHALON's approval, which shall not be
            unreasonably withheld or delayed, artwork proofs of all labels,
            package inserts and packaging prior to use by ABBOTT.

VI. FORECASTS AND ORDERS

      6.1   Orders and Forecasts. Upon the execution of this Agreement, ABBOTT
            shall deliver to CEPHALON or CEPHALON's designee an approximately
            [**] supply (based on historical usage) of Product, including
            samples. At the same time, CEPHALON shall provide ABBOTT with a
            purchase order with CEPHALON's Product requirements, including
            samples for the [**] period commencing with the month which contains
            the effective date of this Agreement. CEPHALON shall also provide a
            forecast of its requirements for Product, including samples, for an
            additional [**] period following the initial [six (6) month] period.
            The [**] forecast shall represent CEPHALON's reasonable estimates
            only, not purchase orders, to facilitate ABBOTT's planning.

      6.2   Forecasts Changes and Forecast Updates. On or before the [**] of
            each month thereafter, CEPHALON shall provide ABBOTT with an
            additional [**] purchase order to supplement the remaining [**] of
            firm purchase orders, thereby establishing a new [**] period of
            purchase orders, and shall provide an updated forecast of its
            estimated requirements of Product for the [**] succeeding such new
            [**] period of firm purchase orders. Provided CEPHALON's purchase
            orders do not exceed ABBOTT's reserve capacity set forth in Schedule
            E, ABBOTT shall accept all CEPHALON purchase orders and shall supply
            CEPHALON in accordance with them. CEPHALON can increase or decrease
            its firm order quantities with ABBOTT's prior agreement and ABBOTT
            can adjust its shipping quantities with CEPHALON's prior agreement.
            Both parties shall use their commercially reasonable efforts to
            accommodate reasonable change requests from the other.

VII. PRICE, SHIPMENT AND PAYMENT

      7.1   ABBOTT's Responsibilities. ABBOTT will properly prepare the Product
            so that it may be lawfully and safely shipped to CEPHALON or its
            designee in the United States. ABBOTT will prepare and execute all
            reasonably necessary shipping documents, consisting of Packing List,
            Dangerous Goods Declaration, and MSDS. CEPHALON will choose the
            carrier by indicating the same on its purchase order provided to
            ABBOTT.

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

      7.2   Terms of Shipment. ABBOTT will ship Product F.O.B. ABBOTT's
            facility. Shipment shall be made by common carrier designated by
            CEPHALON to the shipping point designated by CEPHALON. If CEPHALON
            does not designate a common carrier, Abbott may select the common
            carrier. Risk of loss shall pass from ABBOTT to CEPHALON when the
            Product is delivered to the common carrier. All transport costs will
            be borne by CEPHALON.

      7.3   Price. ABBOTT shall invoice CEPHALON a toll fee for all Product
            (except samples and titration packs) delivered at a transfer price
            equal to [**]. The parties agree that until Cephalon has sold the
            Product [**], the toll fee payable hereunder shall be as set forth
            in Schedule D. For samples of Product, including titration packs,
            ABBOTT shall invoice CEPHALON at a [**].

      7.4   Terms of Payment. CEPHALON will pay ABBOTT the toll fee within
            thirty (30) days after the date on which CEPHALON receives said
            invoice from ABBOTT, together with copies of all documentation
            required for Product release as provided in the Quality Manual. Late
            payments shall bear interest at the rate of 1 1/2 % per month, or if
            less, the highest rate permitted under applicable law.

      7.5   Audit. ABBOTT and its Affiliates and CEPHALON and its Affiliates
            will maintain complete and accurate books and records in sufficient
            detail to enable verification of the Net Sales and other costs
            hereunder. Upon reasonable prior notice, each party )or its
            independent public accountants) shall have access to relevant books
            and records of the other party to conduct a review or audit thereof.
            Such access shall be available during normal business hours for a
            period of two (2) years after the termination of this Agreement.

VIII. INSPECTION AND ANALYSIS

      8.1   Inspection by ABBOTT. ABBOTT will analyze each Product lot for
            compliance with the Specifications set forth in Schedule A. ABBOTT
            will send to CEPHALON a certificate of analysis and a certificate of
            release (together with any other documentation required under the
            Quality Manual ) prior to, or together with, each shipment of
            Product. In this regard, ABBOTT agrees to retain all records and
            documents necessary to fulfill the requirements established by all
            applicable regulatory agencies.

      8.2   Inspection by CEPHALON. CEPHALON or its authorized representative
            will inspect all shipments upon their receipt and will report any
            reasonably discernible defects in the Product to ABBOTT [**]. Any
            defects not reasonably discernible will be reported to ABBOTT by
            CEPHALON [**].

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

      8.3   Non-Conforming Product. If any Product does not meet the warranties
            set forth in Section 10, as determined by CEPHALON's testing and
            inspection of the Product, then solely at its option CEPHALON may,
            as its sole remedy, either (i) require that ABBOTT remanufacture or
            repackage (as appropriate) said Product at no charge to CEPHALON and
            pay all round-trip shipping charges to and from the destination of
            the original shipment, or (ii) be relieved of any obligation to pay
            ABBOTT the toll fees otherwise payable for the manufacture of said
            Product, and ABBOTT shall reimburse CEPHALON for the reasonable
            costs incurred by CEPHALON in properly disposing of such
            non-conforming Product. Any notice given hereunder shall specify the
            manner in which the Product fails to conform to the purchase order
            therefor or fails to meet such warranty or the Specifications. If it
            is determined that the nonconformity (a) is due to damage to the
            Product (i) caused by CEPHALON or its agents or (ii) which occurs
            subsequent to delivery of such Product to the carrier at the point
            of origin, ABBOTT shall have no liability to CEPHALON with respect
            thereto and CEPHALON shall pay for such Product in accordance with
            the terms of this Agreement.

      8.4   Independent Testing. If CEPHALON notifies ABBOTT that any Product
            does not meet the warranties in Section 10, and ABBOTT does not
            agree with CEPHALON's position, the parties will attempt to reach a
            mutually acceptable resolution of the dispute. If they are unable to
            do so after a reasonable period of time (such period not to exceed
            one month from the date of original notification), the matter will
            be submitted to an independent testing laboratory acceptable to both
            parties. Both parties will accept the judgment of the independent
            laboratory. The cost of such testing will be borne by the party
            whose position is determined to have been in error. If the Product
            is determined by said independent laboratory to have been
            conforming, then the provisions of Section 8.3 hereof shall not
            apply, and CEPHALON shall not be relieved of its obligations to pay
            ABBOTT for the production of such Product.

IX. REGULATORY MATTERS; REGULATORY FILINGS AND APPROVALS

            General. ABBOTT shall be responsible for obtaining and maintaining
            all site licenses for the manufacture of the Product and shall
            comply on behalf of CEPHALON with other applicable regulations
            promulgated by, but not limited to, the Food and Drug Administration
            ("FDA") in connection with ABBOTT's manufacture of the Product.

X. REPRESENTATIONS AND WARRANTIES

      10.1  General. ABBOTT represents and warrants to CEPHALON that (i) it has
            and will maintain throughout the pendency of this Agreement, the
            expertise, with respect to personnel and equipment, to fulfill the
            obligations established hereunder, and has

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

            obtained all requisite material licenses, authorizations and
            approvals required by federal, state or local government authorities
            including, but not limited to, the FDA, Environmental Protection
            Agency ("EPA"), Occupational Safety and Health Administration
            ("OSHA"), etc. to manufacture the Product; (ii) the production
            facility, equipment and personnel to be employed to formulate and
            package the Product will be qualified to manufacture product
            according to current Good Manufacturing Practices ("cGMP") at the
            time each such batch of Product is produced, and that the production
            facility to be employed is in compliance with all applicable
            material laws and regulations; (iii) there are no pending or
            uncorrected citations or adverse conditions noted in any inspection
            of the production facility to be employed which would cause the
            Product to be misbranded or adulterated within the meaning of the
            federal Food, Drug and Cosmetic Act, as amended; (iv) the execution,
            delivery and performance of this Agreement by ABBOTT does not
            conflict with, or constitute a breach of any order, judgment,
            agreement, or instrument to which ABBOTT is a party; (v) the
            execution, delivery and performance of this Agreement by ABBOTT does
            not require the consent of any person or the authorization of (by
            notice or otherwise) any governmental or regulatory authority (other
            than those relating to the granting of approval to commercialize the
            Product); and (vi) ABBOTT has not been debarred by the United States
            Food and Drug Administration under the Generic Drug Enforcement Act
            of 1992 (or by any analogous agency or under any analogous law or
            regulation), and neither it nor, to its knowledge, any of its
            officers or directors has ever been convicted of a felony under the
            laws of the United States for conduct relating to the development or
            approval of a drug product or relating to the marketing or sale of a
            drug product, and further, to its knowledge, that no individual or
            firm debarred by any governmental authority will participate in the
            performance, supervision, management or review of the production of
            Product supplied to CEPHALON under this Agreement. CEPHALON
            represents and warrants to ABBOTT that (i) the execution, delivery
            and performance of this Agreement by CEPHALON does not conflict
            with, or constitute a breach of any order, judgment, agreement, or
            instrument to which CEPHALON is a party; and (ii) the execution,
            delivery and performance of this Agreement by CEPHALON does not
            require the consent of any person or the authorization of (by notice
            or otherwise) any governmental or regulatory authority (other than
            those relating to the granting of approval to commercialize the
            Product).

      10.2  Manufacturing Warranty. ABBOTT warrants that all Products supplied
            to CEPHALON will be manufactured in accordance with cGMPs and the
            Quality Manual in effect at the time of manufacture.

      10.3  Product Warranty. ABBOTT hereby warrants that all Product delivered
            to CEPHALON (i) will not be adulterated, misbranded, or otherwise
            prohibited within the meaning of any national, state or local law or
            regulation in the

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

            Territory, (ii) have a current shelf life of not less than [**]
            months; and (iii) will conform to Specifications as established in
            Schedule A hereto.

      10.4  Warranty Disclaimer. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT,
            EACH PARTY EXPRESSLY DISCLAIMS ANY WARRANTIES, INCLUDING ANY
            WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE..

XI. QUALITY CONTROL, RECORDS AND INSPECTIONS

      11.1  Product and Component Samples. ABBOTT will maintain a sample of each
            chemical component (including Active Drug Substance) as required by
            applicable regulatory standards or as otherwise mutually agreed by
            CEPHALON and ABBOTT. ABBOTT will be responsible for maintaining
            retention samples of the Product as may be required by applicable
            regulatory standards.

      11.2  Validation. ABBOTT will validate all process, methods, equipment,
            utilities, facilities and computers used in the formulation,
            packaging, storage, testing and release of Product in conformance
            with all applicable laws and regulations. CEPHALON will have the
            right to review the results of said validation upon request.

      11.3  Quality Compliance. ABBOTT will provide CEPHALON with timely
            notification of all significant deviations, notes to file, and other
            deficiencies that may reasonably be expected to impact the quality
            of the Product, as well as all FDA reports regarding testing,
            manufacture, packaging or labeling of the Product.

      11.4  Manufacturing Records. ABBOTT will maintain complete and accurate
            records relating to the Product and the manufacture, packaging,
            labeling and testing thereof for the period required by applicable
            regulatory standards, and ABBOTT shall provide copies thereof to
            CEPHALON upon CEPHALON's request. The records shall be subject to
            audit and inspection under this Article XI.

      11.5  Batch Records. Records which include the information relating to the
            manufacturing, packaging and quality operation for each lot of
            Product will be prepared by ABBOTT at the time such operations
            occur. ABBOTT will prepare such records in accordance with cGMP's,
            the Specifications and the Quality Manual.

      11.6  Records Retention. ABBOTT will retain records and documents for
            periods meeting all applicable regulations of the FDA.

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

      11.7  Regulatory Inspections. ABBOTT will promptly inform CEPHALON of any
            contact, inspection or audit by any governmental agency (other than
            EPA and OSHA inspections), related to or affecting the Product
            (other than contacts, inspections or audits affecting products
            generally). ABBOTT will promptly provide CEPHALON with copies of any
            government-issued inspection observation reports (including without
            limitation FDA Form 483s and equivalent forms from other regulatory
            bodies) and agency correspondence, that may reasonably be expected
            to adversely affect the Product. ABBOTT and CEPHALON will cooperate
            in resolving any concerns with any governmental agency. ABBOTT will
            also inform CEPHALON of any action taken by any governmental agency
            against ABBOTT or any of its officers and employees which may
            reasonably be expected to adversely affect the Product or ABBOTT's
            ability to supply Product hereunder within 24 hours after the action
            is taken.

      11.8  CEPHALON Inspections. CEPHALON employees or CEPHALON authorized
            representatives will have the right during normal business hours, at
            reasonable intervals and on reasonable prior notice, to conduct [**]
            inspection per [**], at CEPHALON's sole expense, of ABBOTT's
            facilities used in the manufacturing, packaging, storage, testing,
            shipping or receiving of Product Commodities and Components. All
            such employees and representatives shall be qualified to conduct
            such inspections, shall be escorted by ABBOTT employees or
            representatives at all times while at ABBOTT's facility, shall be
            bound by the same confidentiality obligations as contained herein,
            and shall abide at all times with ABBOTT's rules and regulations,
            including without limitation safety rules and regulations. Such
            inspections may include GMP inspections and system audits. Persons
            conducting such inspections will have access only to documents,
            records, reports, data, procedures, facilities, regulatory
            submissions, and all other information required to be maintained by
            applicable government regulations relating directly to the Product.
            ABBOTT shall take appropriate actions to adopt reasonable
            suggestions of CEPHALON to correct any deficiencies identified by
            such inspection or audit. In addition, CEPHALON shall have the right
            to observe from time to time the manufacture, packaging and quality
            control testing of the Product by ABBOTT. No testing of the Product
            by CEPHALON and no inspection or audit by CEPHALON of the ABBOTT
            production facility under this Agreement shall operate as a waiver
            of or otherwise diminish ABBOTT's responsibility with respect to
            Product quality under this Agreement. The duration of an audit will
            be limited to no more than [**] (audits that last over [**] will be
            charged at ABBOTT's specified FTE rates), and audits may not
            interfere with ABBOTT's normal operations.

XII. COMPLAINTS, ADVERSE EXPERIENCES AND RECALLS

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

      12.1  Product Complaints and AE's. CEPHALON shall maintain complaint files
            with respect to the Product in accordance with cGMPs. ABBOTT will
            promptly notify CEPHALON by facsimile transmission of all Product
            complaints and AEs received by ABBOTT within [**] days of its
            receipt thereof. All such notices shall be sent to the attention of
            the Director, Medical Affairs at CEPHALON, facsimile number (610)
            738-6313. CEPHALON shall promptly provide ABBOTT with copies of any
            complaints received by CEPHALON relating to the manufacture or
            packaging of the Product. CEPHALON shall have responsibility for
            responding to all complaints, and for promptly providing ABBOTT with
            a copy of any responses to complaints relating to the manufacture or
            packaging of the Product. CEPHALON or its affiliates shall have
            responsibility for reporting all complaints relating to the Product
            to the FDA and any other regulatory authorities, including, but not
            limited to, complaints relating to the manufacture or packaging of
            the Product as well as adverse experience (AE) reports. CEPHALON
            will correspond with complainants as to any complaints associated
            with Product, whether received during or after the term hereof.
            ABBOTT will assist CEPHALON in investigating Product complaints
            relating to the manufacture or packaging of the Product by analyzing
            Product, manufacturing processes and components to determine the
            nature and cause of an alleged Product manufacturing defect or
            alleged Product failure. ABBOTT will also assist CEPHALON in the
            investigation of any Adverse Experience (AE) reported to either
            party when such AEs are reasonably believed to be attributable to
            the manufacture or packaging of the Product. If CEPHALON determines
            that any reasonable physical, chemical, biological or other
            evaluation should be conducted in relation to an AE or Product
            complaint relating to the manufacture or packaging of the Product,
            ABBOTT will conduct the evaluation and provide CEPHALON with a
            written report of such evaluation within thirty (30) days from
            receipt of CEPHALON's written request for same, together with
            samples of the Product from the relevant lot.

      12.2  Recall Action. If CEPHALON should elect or be required to initiate a
            Product recall, withdrawal or field correction because of (i) supply
            by ABBOTT of Product that does not conform to the Specifications and
            warranties established by this Agreement or (ii) the negligent or
            intentional wrongful act or omission of ABBOTT, CEPHALON will notify
            ABBOTT and provide ABBOTT a copy of its recall letter prior to
            initiation of the recall. ABBOTT will assist CEPHALON (and its
            designated Affiliate) in an investigation to determine the cause and
            extent of the problem. All regulatory authority contacts and
            coordination of any recall activities will be initiated by, and will
            be the sole responsibility of, CEPHALON.

      12.3  Recall Expenses. If any Product is recalled as a result of (i)
            supply by ABBOTT of Product that does not conform to the warranties
            contained in Sections 10.1, 10.2 and 10.3 hereof or (ii) the
            negligent or intentional wrongful act or omission

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

            of ABBOTT, then ABBOTT will bear all reasonable costs and expenses
            of such recall. Recalls for any other reason will be at CEPHALON's
            sole expense. Notwithstanding the foregoing or any other provision
            of this Agreement, ABBOTT's aggregate liability with regard to
            Product recalls shall not exceed the amount of consideration
            received by ABBOTT from CEPHALON hereunder.

      12.4  Recall Records. ABBOTT will maintain complete and accurate records
            for such periods as may be required by applicable law or regulation.

XIII. INSURANCE

      13.1  During the term hereof, ABBOTT shall maintain product
            liability/completed operations insurance, providing coverage of not
            less than [**] per occurrence and in the aggregate, insuring ABBOTT
            against all costs, fees, judgments, and liabilities arising out of
            or alleged to arise out of its obligations and representations and
            warranties under this Agreement. In addition, ABBOTT will maintain
            at all times sufficient property casualty insurance to cover the
            total quantity of Active Drug Substance and Product on hand at its
            full cost of replacement. ABBOTT will provide to CEPHALON, upon
            request, evidence of such insurance coverages. ABBOTT further agrees
            to cause such policies to name CEPHALON as an additional insured at
            no cost to CEPHALON.

      13.2  During the term hereof, CEPHALON agrees to maintain, and upon
            request, to provide evidence of product liability insurance for and
            providing coverage of not less than [**] per occurrence and in the
            aggregate providing a defense for and insuring CEPHALON against all
            costs, fees, judgments and liabilities arising out of or alleged to
            arise out of its obligations and representations and warranties
            under this Agreement. CEPHALON will provide to ABBOTT, upon request,
            evidence of such insurance coverages. CEPHALON further agrees to
            cause such policies to name ABBOTT as an additional insured at no
            cost to ABBOTT.

XIV. TRADEMARKS

      14.1  ABBOTT shall have the non-exclusive right to use the Trademarks in
            packaging the Product in connection with fulfilling its obligations
            hereunder. The rights granted ABBOTT hereunder to use the Trademarks
            shall in no way affect CEPHALON's ownership of such Trademarks. No
            other right, title or interest in the Trademarks is established
            hereby, and nothing herein shall be construed to grant any right or
            license to ABBOTT to use the CEPHALON trademark or the name
            CEPHALON, other than as specifically set forth herein.

      14.2  ABBOTT will only market the Product using the relevant Trademarks as
            listed in Schedule A during the term of this Agreement. Upon
            termination of this

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

            Agreement, ABBOTT will cease all use of the Trademarks and cancel
            any license to such Trademarks granted hereunder.

      14.3  ABBOTT will use the Trademarks in strict accordance with the
            instructions given by CEPHALON, and shall refrain from making any
            changes in connection therewith without first obtaining CEPHALON's
            written consent.

      14.4  In the event of any claim or litigation by a third party against
            ABBOTT alleging that any of the Trademarks imitates or infringes a
            trademark of such third party or is invalid, ABBOTT shall promptly
            give notice of such claims or litigation to CEPHALON and CEPHALON
            shall assume responsibility for and control of the handling,
            defense, or settlement thereof. ABBOTT shall cooperate fully with
            CEPHALON during the pendency of any such claim or litigation, at
            CEPHALON's expense. CEPHALON shall keep ABBOTT notified of the
            current status of any trademark claim, litigation or infringement of
            any of the Trademarks and shall permit ABBOTT to assume the
            handling, defense or settlement thereof if CEPHALON declines to do
            so, at ABBOTT's expense. CEPHALON may at any time modify, adopt or
            withdraw from use any Trademark without any liability to ABBOTT.

XV. INVENTIONS

      Any inventions, discoveries, improvements, or trade secrets made by ABBOTT
in the performance of this Agreement as they may specifically relate to the
Product or its manufacture (including any new use or any change in the method of
producing, testing or storing the Product) shall be owned by CEPHALON, and
ABBOTT shall have a non-exclusive, perpetual, royalty-free worldwide license to
use any such invention, discovery, improvement, or trade secret. ABBOTT shall
execute such instruments as shall be required to evidence or effectuate the
other party's ownership of any such inventions, and shall cooperate upon
reasonable request (and at the expense of the requesting party) in the
prosecution of patents and other intellectual property rights related to any
such invention.

XVI. INDEMNIFICATION

      16.1  By ABBOTT. ABBOTT will indemnify and hold CEPHALON, its Affiliates,
            directors, officers, employees, agents, successors, and assigns
            harmless from any and all liability, damage, loss, cost, or expense
            (including reasonable attorneys' fees) arising out of third-party
            claims, which arise from i) ABBOTT's breach of any of the
            warranties, and representations contained in Article X hereof, or
            ii) ABBOTT's negligence or other willful misconduct. .

      16.2  By CEPHALON. CEPHALON will indemnify and hold ABBOTT, its
            Affiliates, directors, officers, employees, agents, successors, and
            assigns harmless from any

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

            and all liability, damage, loss, cost, or expense (including
            reasonable attorneys' fees) arising out of third party claims
            relating to this Agreement, other than that arising from i) ABBOTT's
            breach of any of the warranties and representations contained in
            Article X hereof or ii) ABBOTT's negligence or other willful
            misconduct.

      16.3  By Each Party. In the event that negligence or willful misconduct of
            both ABBOTT and CEPHALON contribute to any such loss, damage, claim,
            injury, cost or expense, ABBOTT and CEPHALON will each indemnify and
            hold harmless the other with respect to that portion of the loss,
            damage, claim, injury, cost or expense attributable to its
            negligence or willful misconduct.

      16.4  Procedures. In the event that one party receives notice of a claim,
            lawsuit, or liability for which it is entitled to indemnification by
            the other party, the party receiving notice shall give prompt
            notification to the indemnifying party. The party being indemnified
            shall cooperate fully with the indemnifying party throughout the
            pendency of the claim, lawsuit or liability, and the indemnifying
            party shall have complete control over the conduct and disposition
            of the claim, lawsuit, or liability including the retention of legal
            counsel engaged to handle such matter. The indemnifying party
            hereunder will not be liable for any costs associated with the
            settlement of any claim or action brought against it or the other
            party unless it has received prior notice of the settlement
            negotiations and has agreed to the settlement.

XVII. LIMITATION OF LIABILITY

      IN NO EVENT SHALL ABBOTT OR CEPHALON BE LIABLE TO THE OTHER FOR ANY
SPECIAL, INCIDENTAL, CONSEQUENTIAL OR INDIRECT DAMAGES ARISING IN ANY WAY OUT OF
THE MANUFACTURE AND SUPPLY OF THE PRODUCT TO THE OTHER HOWEVER CAUSED AND BASED
ON ANY THEORY OF LIABILITY; PROVIDED HOWEVER, THIS LIMITATION SHALL NOT APPLY TO
THIRD PARTY CLAIMS FOR WHICH THE OTHER PARTY IS INDEMNIFIED HEREUNDER.

XVIII. CEPHALON SUPPLY OF PRODUCT TO ABBOTT

      Upon the termination of this Agreement, Cephalon agrees to negotiate in
good faith with Abbott with respect to CEPHALON supplying ABBOTT, ABBOTT
Affiliates and ABBOTT sublicensees with their respective requirements of Product
and samples for sale, distribution and use outside of the Territory. This
provision shall survive the termination of this Agreement.

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

XIX. TERMINATION

      19.1  Without Cause. Either party may terminate this Agreement, effective
            on the [**] anniversary of the date hereof or on subsequent [**]
            anniversary date(s), if applicable, by giving [**] prior written
            notice to the other party.

      19.2  Breach. If either party hereto commits a material breach of any of
            its obligations hereunder, the non-breaching party may, at its
            option, terminate this Agreement by giving the other party at least
            ninety (90) days prior written notice of its intent to terminate
            this Agreement, which notice shall specify the breach and the
            termination date, unless the breaching party cures said breach prior
            to the specified termination date (or prior to the expiration of a
            longer period as may be reasonably necessary to cure a breach,
            provided that the breaching party is making diligent efforts to cure
            such breach, and provided further that such longer period shall not
            in any event exceed [**] from the date of notice).

      19.3  Insolvency. Either party may terminate this Agreement immediately in
            its entirety if the other Party files a petition of bankruptcy, is
            adjudged bankrupt, takes advantage of any insolvency act, or
            executes a bill of sale, deed of trust, or assignment for the
            benefit of creditors.

      19.4  Survival. The rights and obligations contained in sections covering
            representations and warranties, indemnification and confidentiality
            will survive termination of this Agreement, as will any rights to
            payment or other rights or obligations that have accrued under this
            Agreement prior to termination. Termination will not affect the
            liability of either party by reason of any act, default, or
            occurrence prior to said termination.

      19.5  Transfer. If either party terminates this Agreement, ABBOTT will
            upon request and at CEPHALON's expense provide reasonable assistance
            in transferring production of Product to a facility owned by
            CEPHALON or a third party selected by CEPHALON.

      19.6  Return of Product and Components. Upon termination under this
            Article, ABBOTT shall, at CEPHALON's expense, return promptly to
            CEPHALON all Product, Active Drug Substance, Commodities, Components
            and in process materials in its possession on the effective date of
            termination. CEPHALON shall [**] for all such Product, Active Drug
            Substance, Commodities, Components and in-process materials.

XX. ALTERNATE DISPUTE RESOLUTION

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

      Any dispute concerning or arising out of this Agreement or concerning the
existence or validity hereof, shall be determined by the following procedure.

      20.1  Both parties understand and appreciate that their long term mutual
            interest will be best served by effecting a rapid and fair
            resolution of any claims or disputes which may arise out of services
            performed under this contract or from any dispute concerning
            contract terms. Therefore, both parties agree to use their best
            efforts to resolve all such disputes as rapidly as possible on a
            fair and equitable basis. Toward this end both parties agree to
            develop and follow a process for presenting, rapidly assessing, and
            settling claims on a fair and equitable basis.

      20.2  If any dispute or claim arising under this contract cannot be
            readily resolved by the parties pursuant to the process described in
            Section 20.1, the parties agree to refer the matter to a panel
            consisting of one (1) senior executive employed by each party who is
            not directly involved in the claim or dispute for review and
            resolution. A copy of the contract terms, agreed upon facts (and
            areas of disagreement), and concise summary of the basis for each
            side's contentions will be provided to both such senior executives
            who shall review the same, confer, and attempt to reach a mutual
            resolution of the issue.

      20.3  If the matter has not been resolved utilizing the process set forth
            in this Article XX, and the parties are unwilling to accept the
            non-binding decision of the panel, either or both parties may elect
            to pursue resolution through litigation, or other legal remedies
            available to the parties.

XXI. MISCELLANEOUS

      21.1  Headings. The headings and captions used herein are for the
            convenience of the parties only and are not to be construed to
            define, limit or affect the construction or interpretation hereof.

      21.2  Severability. In the event that any provision of this Agreement is
            found to be invalid or unenforceable, then the offending provision
            shall not render any other provision of this Agreement invalid or
            unenforceable, and all other provisions shall remain in full force
            and effect and shall be enforceable, unless the provisions which
            have been found to be invalid or unenforceable shall substantially
            affect the remaining rights or obligations granted or undertaken by
            either party.

      21.3  Entire Agreement. This Agreement, including all those Schedules
            appended hereto, contains the entire agreement of the Parties
            regarding the subject matter hereof and supersedes all prior
            agreements, understandings or conditions (whether oral or written)
            regarding the same. Further, this Agreement may not

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

            be changed, modified, amended or supplemented except by a written
            instrument signed by both parties.

      21.4  Assignability. This Agreement and the rights hereunder may not be
            assigned or transferred by either party without the prior written
            consent of the other party, provided however, that either party may
            assign this Agreement to an Affiliate, and provided further that in
            the event of a merger, acquisition or sale of substantially all of
            the assets of either party, the rights and obligations of such party
            under this Agreement may be assigned to the survivor or purchaser in
            that transaction. In the event that this Agreement is assigned, it
            shall be binding upon and inure to the benefit of the parties and
            their respective successors and assigns.

      21.5  Further Assurances. Each party hereto agrees to execute, acknowledge
            and deliver such further instruments, and to take such other
            actions, as may be necessary or appropriate in order to carry out
            the purposes and intent of this Agreement.

      21.6  Waiver. The waiver by either party of a breach of any provisions
            contained herein shall be effective only if made in writing and
            shall in no way be construed as a waiver of any succeeding breach of
            such provision or the waiver of the provision itself.

      21.7  Force Majeure. A party shall not be liable for nonperformance or
            delay in performance (other than of obligations regarding any
            payments or of confidentiality) caused by any event reasonably
            beyond the control of such party including, without limitation,
            wars, hostilities, revolutions, riots, civil disturbances, national
            emergencies, strikes, lockouts, unavailability of supplies,
            epidemics, fires, floods, earthquakes, other forces of nature,
            explosions, embargoes, or any other Acts of God, or any laws,
            proclamations, regulations, ordinances, or other acts or orders of
            any court, government or governmental agency. Any occurrence of
            Force Majeure shall be reported promptly to the other party. A party
            whose performance has been excused will perform such obligation as
            soon as is reasonably practicable after the termination or cessation
            of such event or circumstance.

      21.8  Remedies. Each party agrees and acknowledges that its disclosure of
            Confidential Information in breach of this Agreement may cause
            irreparable harm to other party, and therefore that any such breach
            or threatened breach may entitle such party to injunctive relief, in
            addition to any other legal remedies available in a court of
            competent jurisdiction.

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

      21.9  Governing Law. This Agreement shall in all respects be construed and
            enforced in accordance with the law of the State of Illinois.

      21.10 Independent Contractors. The parties are independent contractors
            under this Agreement. Nothing contained in this Agreement is to be
            construed so as to constitute CEPHALON and ABBOTT as partners,
            agents or employees of the other, including with respect to this
            Agreement. Neither party hereto shall have any express or implied
            right or authority to assume or create any obligations on behalf of,
            or in the name of, the other party or to bind the other party to any
            contract, agreement or undertaking with any third party unless
            expressly so authorized in writing by the other party.

      21.11 Counterparts. This Agreement may be executed in multiple
            counterparts, each of which shall be considered and shall have the
            force and effect of an original.

      21.12 Notices. Except as set forth in Section 12.1 above, or as otherwise
            stated herein, all notices, consents or approvals required by this
            Agreement shall be in writing and sent by certified or registered
            air mail, postage prepaid or by facsimile or cable (confirmed by
            such certified or registered mail) to the parties at the following
            addresses or such other addresses as may be designated in writing by
            the respective parties. Notices shall be deemed effective on the
            date of mailing.

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

            If to CEPHALON:

            Sr. Director, Technical Operations
            CEPHALON, Inc.
            145 Brandywine Parkway
            West Chester, PA 19380-4245
            Facsimile:  (610) 738-6640

            All ABBOTT invoices and/or charges in billing should be directed to
            the Accounting Department at:

            CEPHALON, Inc.
            145 Brandywine Parkway
            West Chester, PA  19380-4245
            Attention:  Accounts Payable

            If to ABBOTT:

             Abbott Laboratories
            100 Abbott Park Road
            Abbott Park, IL 60064-6049
            Facsimile:

            All CEPHALON purchase orders shall be sent to:

            Abbott Laboratories
            PPD Manufacturing Services
            Dept. 53T, Building A-3
             1401 Sheridan Dr.
            North Chicago,  IL 60064-6321

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

      IN WITNESS WHEREOF, the undersigned parties have caused this Agreement to
be executed as of the date first above written.

                                        CEPHALON, INC.

                                        By:  /s/ Frank Baldino, Jr.
                                            ------------------------------------

                                        ABBOTT LABORATORIES

                                        By: /s/ Arthur J. Higgins
                                           -------------------------------------

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

                                   Schedule A

        Active Drug Substance, Commodities and Components Specifications

The parties have agreed upon all those applicable specifications for the Active
Drug Substance, Commodities and Components as set forth in the following
documents. The parties shall agree upon any modifications to any such
specifications.

            [**]

TRADEMARKS

[GRAPHIC OMITTED][GRAPHIC OMITTED]

Gabitril(R)

Cephalon(R)

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

                                   Schedule B

                             Form of Quality Manual

                               ABBOTT LABORATORIES

[GRAPHIC OMITTED]

                       PHARMACEUTICAL PRODUCTS DIVISION

                                GENERAL PRACTICE                          PAGE 1

                                DOCUMENT GP. 0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------
TITLE   QUALITY MANUAL TEMPLATE FOR PRODUCTS MANUFACTURED FOR THIRD PARTY
--------------------------------------------------------------------------------
REFERENCE DOCUMENTS

N/A
--------------------------------------------------------------------------------
DISTRIBUTION

N/A
--------------------------------------------------------------------------------
        NC PLANT QA/QC          API PLANT QA/QC           AP16 PLANT QA/QC

NAME:   L. GUTIERREZ            N. MALDONADO              J. BURNS

DATE:   03/02/2000              02/16/2000                02/24/2000

        QA DOCUMENTATION        PARD                      MFG SVCS

NAME:   R. HSU-BEISCHER         P. KLEMENS                A. ROSENSTON

DATE:   05/01/2000              04/24/2000                03/06/2000

        SUPPLIER QA             VALIDATION                DIV QA

NAME:   E. SHADA                C. JAMROG                 A. SCOTT

DATE:   02/11/2000              04/19/2000                04/14/2000
--------------------------------------------------------------------------------
ATTACHMENTS

COMPUTERIZED A-3
--------------------------------------------------------------------------------
APPLICABLE DOCUMENTS
GP.0086
--------------------------------------------------------------------------------

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 26

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

I. PURPOSE

      To establish a procedure for Quality Manual preparation and revision.

II. SCOPE

      This practice applies to all marketed products manufactured by Abbott
      Laboratories for a Third Party.

III. DEFINITION

      A Quality Manual is a controlled document, the purpose of which is to
      address and delineate the responsibilities between contracting parties.
      The contents are specific as to products, packages, services, and
      Contractors to the Pharmaceutical Products Division (PPD), Abbott
      Laboratories.

IV. PROCEDURE

      A.    A Quality Manual shall be established between Abbott Laboratories
            and a Third Party when Abbott Laboratories is acting as a contractor
            and is contracted to manufacture, package, or supply product support
            for a product or an intermediate step of manufacturing.

      B.    When establishing a Quality Manual, a template (Attachment A) should
            be used as a guideline. Note, that the information and wording in
            the template is not absolute but illustrates information and issues
            that need to be discussed when developing the working relationship
            between Abbott Laboratories and the Third Party.

            Attachment A - Abbott Laboratories as the manufacturing company and
            a Third Party as the contracting company.

      C.    Once the Quality Manual has been drafted by Abbott Laboratories and
            verbally agreed upon by both parties, the Quality Manual shall
            obtain written approval via PPD's document change control process
            (GP.0086, Initiation, Review, and Approval of Division Document
            Change Requests).

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 27

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

IV. PROCEDURE (Cont.)

      D.    Approved Quality Manuals shall be registered and released into DMS
            by PPD QA Documentation (D-44T).

      E.    Any subsequent changes/updates to a Quality Manual shall route for
            approval via PPD's document change control process (GP.0086).

V. ANNUAL REVIEW

      Quality Manuals will be reviewed for current applicability by PPD
      Manufacturing Services (D-554), in conjunction with the Third Party, on an
      annual basis. A record of this review will be kept in the Quality Manual
      file in QA Documentation (D-44T).

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 28

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

                                 ATTACHMENT A-3

TABLE OF CONTENTS

I. PURPOSE

II. SCOPE

III. QUALITY AGREEMENT

IV. POLICIES AND PROCEDURES

      A.    Document Control

              1.    Product Specification
              2.    Testing and Sampling Specification
              3.    Packaging and Labeling Specifications
              4.    Batch Record
              5.    Specification Approval
              6.    Document Distribution
              7.    Compendial Compliance
              8.    Filing Requirements
              9.    DMF Requirements
              10.   Annual Update Requirements

      B.    Materials

              1.    Third Party Controlled Material (if applicable)
              2.    Printed Material (if applicable)

      C.    Specifications, Sampling, Testing, & Release of Product

      D.    Validation

      E.    Environment

              1.    Storage Conditions
              2.    Controlled Drug Requirements
              3.    Environmental Monitoring

      F.    Stability

      G.    File Samples

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 29

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

      H.    Deviations

      I.    Nonconformances

      J.    Reinspection

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 30

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

                             ATTACHMENT A-3 (Cont.)

                            TABLE OF CONTENTS (Cont.)

IV. POLICIES AND PROCEDURES (Cont.)

      K.    Reprocessing and Rework

      L.    Audits and Monitoring

      M.    Annual Product Review

      N.    Product Complaints

      O.    Shipping Instructions

V. APPENDIX

      A.    Key Contact Information

      B.    Product Description

      C.    Definitions

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 31

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

                             ATTACHMENT A-3 (Cont.)

I. PURPOSE

      The Quality Manual defines a working agreement between Abbott Laboratories
      Pharmaceutical Products Division (PPD) and [TP NAME], to establish quality
      program requirements and delineate quality control responsibilities to
      assure that any product manufactured by PPD is processed by procedures
      which meet [TP NAME] specifications and applicable government regulations,
      including the current Code of Federal Regulations, Current Good
      Manufacturing Practices for the Manufacture, Processing, Packing, or
      Holding of Drugs, and as defined in applicable Supply Agreements.

II. SCOPE

      This Quality Manual applies to all contract operations at Abbott
      Laboratories for [TP NAME], for (PRODUCT DESCRIPTION, e.g., oral dosage
      form soft elastic gelatin capsule).

III. QUALITY AGREEMENT

      The policies and procedures stated herein shall be adhered to in the
      supply of and processing of drug products by Abbott Laboratories and [TP
      NAME].

      [TP NAME] shall notify PPD Supplier Quality Assurance whenever there is a
      significant change in management or company ownership.

IV. POLICIES AND PROCEDURES

      A.    Document Control

            1.    Production Specifications

            The "production" specifications are the documents which specify the
            manufacturing and/or finishing instructions and related bills of
            material used in the production process. These production
            specifications are developed and/or approved by ABBOTT LABORATORIES
            and [TP NAME] using [TP NAME] master formulas and technical support.

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 32

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

                            ATTACHMENT A-3 (Cont.)

IV. POLICIES AND PROCEDURES (Cont.)

      A.    Document Control (Cont.)

            2.    Testing and Sampling Specifications

                  The "testing and sampling" specifications are the documents
                  which specify the testing procedures and the sampling
                  instructions necessary to evaluate a commodity, material or
                  product against applicable acceptance/release requirements
                  within PPD testing facilities and laboratories. These testing
                  and sampling specifications are developed and/or approved by
                  ABBOTT LABORATORIES and [TP NAME].

            3.    Packaging and Labeling Specifications

                  The "packaging and labeling" specifications are the documents
                  which describe the labeling artwork and commodity
                  specifications and drawings used in the finishing of the
                  product. These packaging and labeling specifications are
                  developed and/or approved by ABBOTT LABORATORIES and [TP
                  NAME].

            4.    Batch Record

                  Batch Records will be maintained by the appropriate
                  organizational unit within ABBOTT LABORATORIES. Batch Records
                  are available on site for inspection and review by [TP NAME]
                  and/or its agents.

            5.    Specification Approval

                  Specification initiation or revision that affects the
                  scientific or technical content requires approval before
                  proposed changes are implemented. This applies to
                  manufacturing, finishing, testing, storage, labeling of the
                  product as well as any changes to the material specification
                  for component and finished product. Editorial or format
                  changes to applicable specifications, not affecting the
                  scientific/technical content or intent of the specification,
                  will not require approval by [TP NAME]. Those documents
                  requiring [TP NAME] approval are as follows:

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 33

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

                             ATTACHMENT A-3 (Cont.)

IV. POLICIES AND PROCEDURES (Cont.)

      A.    Document Control (Cont.)

            5.    Specification Approval (Cont.)

                  S43D       Manufacturing Directions (FDA Document)
                  S43MI      Manufacturing Instructions
                  S43CO      Coating Specifications
                  S43Y       Drying Specifications
                  S43T       Technical Specifications
                  S41        Acceptance/Release Specifications for Final Product
                  S02        Printed Commodity Specifications
                  S03        Drug Code Specifications
                  S42        Standard Test Method for Final Product
                  PCA        Primary Container Approval
                  PSCN       Printed Supplies Control Notice

                  Document Change Requests (CR) will be forwarded to [TP NAME]
                  via appropriate mail or facsimile.

                  When [TP NAME] initiates a change request on an applicable
                  specification, PPD QAD shall be provided the proposed
                  specification and appropriate documentation which summarizes
                  and justifies each change.

            6.    Documentation Distribution

                  [TP NAME] shall be on distribution for all applicable
                  specification documents used in the manufacturing/
                  finishing/release of the product and in the acceptance of raw
                  materials going into the finished product.

                  On a quarterly basis, [TP NAME] will be provided a list of
                  distributed specifications to verify receipt of most current
                  version. ABBOTT LABORATORIES shall be on distribution for [TP
                  NAME] drug product acceptance/release specifications to
                  maintain consistency between the two facilities.

            7.    Compendial Compliance

                  Compliance to compendial requirements is the responsibility of
                  both [TP NAME] and ABBOTT LABORATORIES.

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 34

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

                             ATTACHMENT A-3 (Cont.)

IV. POLICIES AND PROCEDURES (Cont.)

      A.    Document Control (Cont.)

            8.    Filing Requirements

                  [TP NAME] is the owner of the product and is responsible for
                  annual reports and any other regulatory filings. During the
                  Preapproval Inspection/Postapproval Inspection,
                  representatives from both [TP NAME] and ABBOTT LABORATORIES
                  shall be present.

            9.    DMF Requirements (Use as Applicable)

                  ABBOTT LABORATORIES shall maintain a Drug Master File. Written
                  authorization granting permission to reference the Master File
                  shall be given to [TP NAME], if requested.

            10.   Annual Update Requirements (Use as Applicable)

                  ABBOTT LABORATORIES shall, upon request, provide [TP NAME]
                  with product related documentation for the purpose of updating
                  regulatory information.

      B.    Materials

            All materials supplied by ABBOTT LABORATORIES for use in the
            product(s) covered by this manual, will be purchased, received,
            inspected, stored, and handled in accordance with ABBOTT
            LABORATORIES' standard operating procedures. All materials shall be
            in accordance with the approved specifications or approved
            nonconforming material reports (NCMR).

            ABBOTT LABORATORIES shall maintain an approved supplier list in
            accordance with ABBOTT LABORATORIES' procedures. [TP NAME] approval
            will be required for any supplier change for materials used in [TP
            NAME] products. Abbott will make the following information available
            upon request:

                    Material Name
                    Supplier Name
                    Manufacturing Location

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 35

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

                            ATTACHMENT A-3 (Cont.)

IV. POLICIES AND PROCEDURES (Cont.)

      B.    Materials (Cont.)

            1.    [TP NAME] Controlled Material (if applicable)

                  Materials controlled by [TP NAME] may be supplied by [TP NAME]
                  to ABBOTT LABORATORIES in accordance with the specifications.
                  If such material is not sourced from an ABBOTT LABORATORIES
                  approved supplier, then [TP NAME] shall be responsible to
                  maintain an Approved Supplier List for each source specified
                  by [TP NAME]. If suppliers of code materials or product
                  contact commodities are not specified by Abbott Laboratories,
                  [TP NAME] shall provide Abbott Laboratories an annual
                  certification that an acceptable supplier evaluation has been
                  completed which includes documentation that compliance to cGMP
                  and [TP NAME] requirements is acceptable. ABBOTT LABORATORIES
                  must be notified if [TP NAME] changes suppliers of raw
                  materials or product contact commodities that they are
                  supplying. ABBOTT LABORATORIES will not be required to receive
                  materials from any source which it feels will or may have a
                  negative impact on its operation.

            2.    Printed Material (if applicable)

                  [TP NAME] shall be responsible for and shall provide ABBOTT
                  LABORATORIES all copy content, artwork, and mechanicals for
                  all printed materials associated with the product. This
                  includes but is not limited to container labels, containers,
                  cartons, package inserts, and promotional material. [TP NAME]
                  shall be responsible for compliance with all federal, state,
                  and local regulations concerning packaging and labeling
                  materials and for obtaining any necessary regulatory approvals
                  of printed materials, artwork, and copy.

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 36

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

                             ATTACHMENT A-3 (Cont.)

IV. POLICIES AND PROCEDURES (Cont.)

      C.    Specifications, Sampling, Testing, & Release of Product

            [TP NAME] shall supply ABBOTT LABORATORIES with all in-process and
            final product release specifications including acceptance limits for
            each required test and any appropriate test methods and supporting
            test method validation.

            All test methodologies will be validated. For those procedures which
            appear in the current USP/NF or other recognized standard reference,
            a statement indicating the reference shall suffice. For those test
            methods which are developed by ABBOTT LABORATORIES, documentation
            supporting the validation of the test method shall be supplied, upon
            request, to [TP NAME]. For those test methods developed by [TP
            NAME], [TP NAME] shall supply ABBOTT LABORATORIES with the
            supporting validation documentation. Upon review of Abbott
            Laboratories' data, [TP NAME] will provide Abbott Laboratories' with
            written authorization verifying Abbott Laboratories ability to
            perform such tests.

            Each lot of product manufactured or packaged by ABBOTT LABORATORIES
            will be sampled and tested in accordance with established Abbott
            Laboratories specifications.

            A Certificate of Analysis (COA)or applicable documentation shall be
            provided to [TP NAME] at (address of [TP NAME]) by ABBOTT
            LABORATORIES. The COA or equivalent will be generated upon
            completion of all testing requirements. The COA or equivalent shall
            contain the items tested, corresponding acceptance criteria, and
            test results. [TP NAME] is responsible for the approval and release
            of all bulk or packaged product after review of Certificate of
            Analysis.

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 37

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

                            ATTACHMENT A-3 (Cont.)

IV. POLICIES AND PROCEDURES (Cont.)

      D.    Validation

            Process, cleaning, equipment, facilities, utilities and computer
            validation protocols unique to [TP NAME] products shall be developed
            by [TP NAME] and ABBOTT LABORATORIES. Protocols shall be agreed upon
            and approved by both parties. ABBOTT LABORATORIES shall perform
            process and cleaning validations using lots of manufactured drug
            product. ABBOTT LABORATORIES shall maintain original validation
            reports and protocols according to Abbott Laboratories procedure and
            provide a copy of the validation reports and protocols to [TP NAME].

            [TP NAME] shall be notified of any proposed process changes. The
            need for revalidation will be determined by ABBOTT LABORATORIES and
            [TP NAME]. The protocol shall be agreed upon and approved by both
            parties.

      E.    Environment (Use sections which apply)

            1.    Storage Conditions

                  Drugs and drug products are to be stored in a secure area,
                  protected from extremes in temperature and humidity in
                  accordance with environmental requirements specified by [TP
                  NAME].

            2.    Controlled Drug Requirements

                  Controlled Drugs are to be manufactured, processed, and
                  secured as outlined in the CFR or other applicable local
                  regulations. Policies and procedures controlling storing and
                  manufacturing of controlled drug shall be approved by [TP
                  NAME].

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 38

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

                             ATTACHMENT A-3 (Cont.)

IV. POLICIES AND PROCEDURES (Cont.)

      E.    Environment (Use sections which apply) (Cont.)

            3.    Environmental Monitoring

                  Where particulate and/or microbial levels are required for the
                  drug product, then the facilities used during the
                  manufacturing and packaging process shall be monitored for
                  these factors. ABBOTT LABORATORIES will be responsible for the
                  establishment and institution of a monitoring program to
                  assure that the drug product will meet the required
                  particulate and microbial levels and shall provide [TP NAME]
                  with access to the records obtained from this monitoring
                  program.

      F.    Stability

            [TP NAME] or ABBOTT LABORATORIES (choose one) shall be responsible
            for stability testing (expand as needed).

      G.    File Samples

            Abbott Laboratories shall be responsible for obtaining, maintaining,
            and examining drug substance and drug product file samples for
            released product as defined in Good Manufacturing Practices. Abbott
            Laboratories PPD shall retain samples of materials and product which
            is finished by Abbott Laboratories as specified in the Abbott
            Sampling Plan Specification. Abbott Laboratories shall notify [TP
            NAME] if any non standard conditions exists.

      H.    Deviations

            A deviation will be used to document any change from the approved
            manufacturing directions or test method. Any deviation or variance
            must be documented and justified in writing.

            Deviations shall require Abbott Laboratories and [TP NAME] approval
            according to company policy before release/acceptance of any
            material.

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 39

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

                             ATTACHMENT A-3 (Cont.)

IV. POLICIES AND PROCEDURES (Cont.)

      H.    Deviations (Cont.)

            [TP NAME] approval shall be obtained in writing (fax confirmation is
            acceptable) for any deviation per Abbott Laboratories standard
            procedures.

            The deviation will become part of the permanent batch record.

      I.    Nonconformances

            Material or product not meeting established specifications are to be
            handled as nonconformances and documented as such, based on ABBOTT
            LABORATORIES standard procedures. Actions taken to investigate the
            nonconformance and to justify the release of the lot of material
            must be fully documented. The nonconformance document (i.e., NCMR)
            will be approved by both ABBOTT LABORATORIES and [TP NAME] as stated
            below. The approved document will become the specification for the
            release of that specific lot of material. Any resulting corrective
            actions shall be followed through to timely closure. Approval by the
            appropriate Quality Assurance functions are solicited and obtained
            via facsimile copy.

             ------------------------------------------------------------------
                      Nonconformance                Approval Requirements
             ------------------------------------------------------------------
             Finished Product                  [TP NAME] and ABBOTT
                                               LABORATORIES
             ------------------------------------------------------------------
             Raw Materials sourced and used    ABBOTT LABORATORIES.
             by ABBOTT LABORATORIES
             ------------------------------------------------------------------
             Drug Substance and Raw Materials  [TP NAME] and ABBOTT
             sourced by [TP NAME] to be used   LABORATORIES
             by ABBOTT LABORATORIES.
             ------------------------------------------------------------------

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 40

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

                            ATTACHMENT A-3 (Cont.)

IV. POLICIES AND PROCEDURES (Cont.)

      J.    Reinspection

            A reinspection is performed under conditions where product quality
            requires reverification. The reinspection work shall be approved and
            performed by ABBOTT LABORATORIES according to established
            procedures. The reinspection work must be documented to state
            reasons, justification, directions for, and results of reinspection.

      K.    Reprocessing and Rework

            Reprocessing and rework activity must be approved by both ABBOTT
            LABORATORIES and [TP NAME]. Reprocessing and rework directions must
            be established to define the process. If the product is part of a
            regulatory filing, reprocessing parameters must have been developed
            and submitted with filing prior to approval. Reprocessing and/or
            rework of material or product must be documented to state reason and
            justification for processing.

      L.    Audits and Monitoring

            Except with respect to information and operations which constitute
            ABBOTT LABORATORIES trade secrets, the [TP NAME] shall have the
            right to inspect ABBOTT LABORATORIES batch records and the portions
            of ABBOTT LABORATORIES facility used for the manufacturing,
            finishing, holding, and testing of [TP NAME] drug products. Audit
            visits are to be arranged with the Quality function of the
            manufacturing facility to be audited. Responses to observations
            written as the result of auditing activities shall be forwarded to
            the auditing company within 30 days from their issuance.

            ABBOTT LABORATORIES shall notify [TP NAME] within a reasonable
            amount of time of any FDA or other applicable regulatory agencies'
            (e.g., DEA) inspections which are related to the product, and shall
            provide copies of any relevant 483(s) (inspection observation
            report) and correspondence as related to the production of [TP NAME]
            product(s). ABBOTT LABORATORIES is responsible for compliance to all
            Federal, State, and Local laws and regulations as they apply to
            ABBOTT LABORATORIES' business.

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 41

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

                             ATTACHMENT A-3 (Cont.)

IV. POLICIES AND PROCEDURES (Cont.)

      M.    Annual Product Review

            [TP NAME] shall be responsible for evaluating the quality standards
            of the drug product to determine the need for changes in the drug
            product specifications of manufacturing or control records in
            accordance with Good Manufacturing Practices as required. An annual
            product review is documented based on [TP NAME] policy. (Indicate
            product review schedule.)

            ABBOTT LABORATORIES shall provide [TP NAME] access to batch records
            on (product name and list numbers) for each lot of drug product
            including data analysis and summary of exception documentation.

      N.    Product Complaints

            Complaints files, as required by Good Manufacturing Practices, shall
            be maintained by [TP NAME]. All complaints received by ABBOTT
            LABORATORIES shall be forwarded to [TP NAME]. [TP NAME] shall be
            responsible for the review of the complaint to determine the need
            for an investigation as specified in applicable regulations or the
            need to report to a regulatory agency. [TP NAME] shall send to
            ABBOTT LABORATORIES all product performance or manufacturing related
            complaints (nonmedical) and medical complaints. ABBOTT LABORATORIES
            shall if requested by [TP NAME] conduct an investigation for each
            nonmedical complaint and shall report the findings and follow-up of
            each investigation to [TP NAME].

            [TP NAME] shall make these complaint files available to ABBOTT
            LABORATORIES onsite or electronically within one business day if
            they are required during a regulatory agency inspection.

      O.    Shipping Instructions

            Abbott Laboratories will control and coordinate all shipping
            activity unless specified by [TP NAME].

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 42

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

                            ATTACHMENT A-3 (Cont.)

V. APPENDIX

      A.    Key Contact Information

                               ABBOTT LABORATORIES

--------------------------------------------------------------------------------
     TITLE                    INDIVIDUAL              PHONE           FAX
--------------------------------------------------------------------------------
Mfg. Services Mgr.
--------------------------------------------------------------------------------
Schedules & Forecasts
--------------------------------------------------------------------------------
Analytical Laboratory
--------------------------------------------------------------------------------
Plant Quality           AP:
                        NC:
                        API:
--------------------------------------------------------------------------------
Quality Assurance
Documentation
Label Dev Control
--------------------------------------------------------------------------------
Certs & File Samples
--------------------------------------------------------------------------------
Product Complaints
--------------------------------------------------------------------------------
PARD
--------------------------------------------------------------------------------
Stability
--------------------------------------------------------------------------------
Validation
--------------------------------------------------------------------------------

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 43

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

                             ATTACHMENT A-3 (Cont.)

V. APPENDIX (Cont.)

      A.    Key Contact Information (Cont.)

                                    [TP NAME]

--------------------------------------------------------------------------------
     TITLE                 INDIVIDUAL              PHONE             FAX
--------------------------------------------------------------------------------
Schedules & Forecasts
--------------------------------------------------------------------------------
Product Complaints
--------------------------------------------------------------------------------
Medical
--------------------------------------------------------------------------------
Labeling
--------------------------------------------------------------------------------
Regulatory
--------------------------------------------------------------------------------
Operations
--------------------------------------------------------------------------------
Technical
--------------------------------------------------------------------------------
Documentation
--------------------------------------------------------------------------------
Quality
--------------------------------------------------------------------------------

      B.    Product Description

            Products currently being manufactured by ABBOTT LABORATORIES for [TP
            NAME].

              Abbott      [TP NAME]
              List        Product                             Manufacturing
              ----        -------                             -------------
              Number      Number            Product Name      Location
              ------      ------            ------------      --------

      C.    Definitions

            1.    Contractor

                  Any manufacturer, packager, or other product support servicer
                  who performs processing and/or packaging of a product or any
                  intermediate step of manufacture, or other product support
                  service, is a contractor.

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 44

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

                             ATTACHMENT A-3 (Cont.)

V. APPENDIX (Cont.)

      C. Definitions (Cont.)

            2. Batch Record

                  The batch record consists of master manufacturing formula,
                  appropriate packaging bill and instructions, and exception
                  documentation, such as NCMRs, deviations, variance reports,
                  and additional documentation which may have been processed as
                  part of the production record of the batch.

            3.    CRB

                  Certification Review Board

            4.    Deviation

                  The document used to obtain approvals to temporarily modify or
                  to document excursions from operating, manufacturing, testing
                  instructions, target/informational test results, or
                  procedures. The deviation does not permanently change existing
                  instructions/BOP's or procedures; it is intended to be a
                  specific/one time use document.

            5.    Lot Number (This definition may be elaborated on for including
                  Control Number or other additional supporting information.)

                  A Lot Number is used to identify a specific lot or batch of
                  manufactured material.

            6.    Material

                  All actives, excipients, printed or unprinted commodities
                  which are used during the manufacturing or finishing process
                  for a product.

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 45

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

                             ATTACHMENT A-3 (Cont.)

V. APPENDIX (Cont.)

      C.    Definitions (Cont.)

            7.    Nonconforming Materials Report (NCMR)

                  A document used for recording review and disposition of
                  nonconforming materials. The NCMR document, when formally
                  approved with appropriate sign-off, becomes the specification
                  for the disposition of that specific lot of material only.
                  Actions taken to investigate the nonconformance and to justify
                  the release of that lot must be fully documented.

            8.    PPD

                  Pharmaceutical Products Division of Abbott Laboratories

            9.    PARD

                  Pharmaceutical and Analytical Research and Development. The
                  research and development group of Abbott Laboratories PPD.

            10.   Product

                  Any product manufactured, packaged and/or labeled by Abbott
                  Laboratories to meet third party requirements for further
                  processing marketing, and/or sale in accordance with the
                  executed supply agreement.

            11.   Reinspection

                  A visual or mechanical evaluation performed to remove/correct
                  defective units for which the process is not expected to have
                  an adverse effect on product quality. Reinspection should
                  involve the use of a deviation except where standard procedure
                  allows for such routine activity in the course of normal
                  processing.

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 46

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

                             ATTACHMENT A-3 (Cont.)

V. APPENDIX (Cont.)

      C.    Definitions (Cont.)

            12.   Reprocessing

                  Duplication of a step or steps currently in the manufacturing
                  formula in order to bring the product into conformance with
                  specifications and which will not alter the safety, identity,
                  strength, quality, or purity of the drug product beyond the
                  established requirements. Reprocessing associated with product
                  having a regulatory submission requires Regulatory Affairs
                  review.

            13.   Rework

                  Any additional steps taken to process a batch (other than
                  reinspection) to bring it into conformance with the
                  specifications and which will not alter the safety, identity,
                  strength, quality, or purity of the drug product beyond the
                  established requirements. All rework must be documented per
                  approved rework documentation requirements and appended to a
                  deviation.

            14.   Instructions for Outside Packaging

                  List Number/Label Code/Size Code specific document supplied by
                  Abbott Laboratories to instruct third parties on how to
                  perform finishing steps for marketed product.

            15.   Package Master (PMV)

                  List Number/Label Code/Size Code specific document specifying
                  all commodities and corresponding quantities used with
                  divisional packaging procedures for finishing of manufactured
                  product.

            16.   PCA: Primary Container Approval

                  Document used to list commodities approved for product contact
                  on a specified list number.

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 47

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

                            ATTACHMENT A-3 (Cont.)

V. APPENDIX (Cont.)

      C.    Definitions (Cont.)

            17.   PSCN: Printed Supplies Control Notice

                  Document which lists printed supplies used during finishing
                  operations.

            18.   S01: Non-Printed Commodity Specification

                  Document containing a general description of the material,
                  what it is made of, and what it looks like.

            19.   S02: Printed Commodity Specification

                  Document applies to the control of product labeling and
                  identifies the properties of the material, size, style, color,
                  and reference marks, as applicable.

            20.   S03: Drug Code Specification

                  A description of the chemical, biological, identification,
                  microbial, and physical requirements of the drug entity with
                  the appropriate acceptance/release and test method
                  requirements; Certificate of Analysis requirements; incoming
                  packing and marking requirements; sampling instructions; and
                  continuing guarantee requirements.

            21.   S05: Sampling Plan Specification

                  Provides sampling instructions related to sample taken, sample
                  amount, test location, and name of required test(s). Also,
                  identifies the associated manufacturing stage where sampling
                  is to occur and requirements for sample packaging and handling
                  may be indicated.

            22.   S41: Acceptance/Release Specification

                  A description of the chemical, biological, identification,
                  microbial, and physical requirements of the drug entity with
                  the appropriate acceptance/release and test method
                  requirements, and sampling instructions.

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 48

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

                             ATTACHMENT A-3 (Cont.)

V. APPENDIX (Cont.)

      C.    Definitions (Cont.)

            23.   S43CO: Coating Specification

                  This document is used by the Plant, when applicable, along
                  with the S43MI, and includes setup parameters for coating
                  equipment, (e.g., exhaust temperature, pan speed) and
                  calculations for amounts of coating liquids.

            24.   S43D: Manufacturing Directions and Formula

                  This is a summary document used for regulatory submissions
                  which consists of the manufacturing directions and formula
                  sections. The manufacturing directions section includes
                  individual steps and equipment required to manufacture the
                  product or material, such as, LOD end points and special
                  mixing/temperature requirements. Critical process parameters
                  are included. The formula section includes a list of
                  ingredients and quantities used in the formulation.

            25.   S43MI: Manufacturing Instructions and Formula

                  This is the document that establishes requirements for the
                  Plant and consists of manufacturing instructions and formula
                  sections. The manufacturing instructions section includes
                  critical process parameters and equipment required to
                  manufacture the product or material, such as, LOD end points
                  and special mixing/temperature requirements. Typically, this
                  section contains more detail than the corresponding section in
                  the S43D. The formula section includes a list of ingredients
                  and quantities used in the formulation.

            26.   S43RD: Reprocessing Directions

                  This is a document submitted to regulatory agencies, which
                  includes the manufacturing steps necessary to reprocess
                  product or material (e.g., recoating, regrinding).

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 49

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

                             ATTACHMENT A-3 (Cont.)

V. APPENDIX (Cont.)

      C.    Definitions (Cont.)

            27.   S43S: Sterilization Process Specification

                  This document is used by the Plant/Suppliers, when applicable.
                  This includes the steps necessary to apply sterilization
                  methods to product, material, or commodities (outside
                  filtration).

            28.   S43T: Technical Processing

                  This document is used by the Plant/Suppliers, when applicable.
                  For manufacturing, the S43T contains technical information not
                  found in the S43MI, but critical for the manufacturing
                  process. Calculation worksheets and requirements for
                  intraplant movement of materials are some examples. For
                  finishing, the S43T contains technical information for types
                  of commodities and equipment (e.g., bottle cleaning,
                  imprinting lot and expiration date).

            29.   S43Y: Drying Specification

                  This document is used by the Plant, when applicable, along
                  with the S43MI and includes set up parameters for drying
                  equipment, such as temperature and time.

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 1

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                      -1-
<PAGE>

[GRAPHIC OMITTED]             ABBOTT LABORATORIES

                       PHARMACEUTICAL PRODUCTS DIVISION

                               GENERAL PRACTICE                          PAGE 2

                               DOCUMENT GP.0074

--------------------------------------------------------------------------------
ISSUE DATE     SUPERCEDES

05/08/2000     07/15/1999
--------------------------------------------------------------------------------

DESCRIPTION OF CHANGE:

CR #                                   INITIATOR

0000480                                L. THOMPSON
--------------------------------------------------------------------------------
D OF C

Clarify Attachment A, Section IV.D. Validation, Add "unique to [TP NAME]
products" to the first sentence after the word "protocols".
--------------------------------------------------------------------------------

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                      -2-
<PAGE>

                                   Schedule C

                             Abbott Reserve Capacity

The minimum annual capacity to be reserved by ABBOTT, is as follows for the
Initial Term of this agreement:

Commercial Product

        2-mg x 100-count      [**]  units per month

        4-mg x 100-count      [**]  units per month

       12-mg x 100-count      [**]  units per month

       16-mg x 100-count      [**]  units per month

Product Samples

        2-mg x 40-count       [**]  units per month

        4-mg x 40-count       [**]  units per month

Titration Packs

        2-mg x 148-count      [**]  units per month

                                      -1-
<PAGE>

                                   Schedule D

        Toll Fee until CEPHALON has sold Product for One Calendar Quarter

Abbott to provide fee which will be based on [**].

                                      -2-<PAGE>

                                                                Exhibit 10.15(b)
August 11, 2000

Mr. Robert P. Roche, Jr.
Senior Vice President
Sales & Marketing
Cephalon, Inc.
145 Brandywine Parkway
West Chester, PA  19380-4245

Dear Mr. Roche:

Thank you for your letter dated July 14, 2000. As mentioned in my prior letter
to you, Bristol-Myers Squibb Company has, effective September 5, 2000,
terminated the Amended and Restated Copromotion Agreement by and between
Bristol-Myers Squibb Company and Cephalon, Inc. effective January 1, 1999 (the
"Agreement"). Under the terms of the Agreement, BMS will pay Cephalon the
compensation to which it is entitled under the Agreement through September 5,
2000. To that end, enclosed is a schedule detailing the compensation to which
Cephalon is entitled for the period beginning January 1, 2000 and ending June
30, 2000. This payment of [**] will be made shortly. In addition, a final
payment will be made to Cephalon for the period beginning July 1, 2000 and
ending September 5, 2000. This payment will be made within 60 days following the
end of such period, as provided in Section 10(d) of the Agreement.

Please contact me at the above address if you have any questions.

                              Very truly yours,

                              /s/ Scott Applebaum

                              Scott Applebaum
                              Associate Counsel

Cc:   A. Coles, M.D.
      D. Snow
      J. A. Smith

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00023-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00023-of-00352.parquet"}]]